In this month's issue
Pfizer has hit the acquisition trail again and is buying FoldRx Pharmaceuticals, in a move that will boost its presence in orphan and rare disease markets World News
AstraZeneca will be celebrating news that its antipsychotic Seroquel XR has been given the European Commission’s seal of approval as an add-on treatment for major depressive episodes in patients with Major Depressive Disorder (MDD).
UK News
Doctors are increasingly encouraged to factor costs into their drug prescribing decisions but very few clinical trials actually detail these costs, a Canadian study has found.
Clinical News
Pfizer has hit the acquisition trail again and is buying FoldRx Pharmaceuticals, in a move that will boost its presence in orphan and rare disease markets
Allergan is the latest company to settle claims of marketing products for non-approved use, securing an agreement over its wrinkle smoother Botox
Merck & Co and partner Cardiome have been granted marketing approval by European regulators for the intravenous formulation of their anti-arrhythmic Brinavess
Nycomed has begun the global market launch of its new chronic obstructive pulmonary disease Daxas, starting off in Germany
Genzyme Corp's chief executive has told Reuters that he is willing to sell the US biotech major to Sanofi-Aventis, but not for the $69 per share offered by the French drugmaker
UK drugmaker Archimedes Pharma will be corking the champagne after receiving a regulatory green light to market its flagship pain spray PecFent (formerly NasalFent) throughout the European Union.
Cancer Research UK has started clinical trials of Merck & Co’s MK-0752 in combination with Eli Lilly’s Gemzar in patients with advanced pancreatic cancer.
Giving GPs responsibility for commissioning alongside service provision is crucial for better integration of health services and thus overall outcomes, a report by The Nuffield Trust has concluded
Bristol-Myers Squibb/Pfizer’s apixaban can more than halve the risk of stroke or systemic embolism compared with aspirin in patients with atrial fibrillation who cannot take warfarin, the results of the AVERROES trial have shown.
Companies “have only scratched the surface” in their efforts to understand patient psychology so that clinical trial protocols can be better geared to meeting recruitment targets, say consultants Cutting Edge Information.
The Institute of Clinical Research in India (ICRI) has formed a strategic partnership with Accenture to develop an educational programme in clinical research and pharmacovigilance.
What is joint working? Find out more here
Find your next job
